Orthofix Medical (OFIX) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
29 Apr, 2026Executive summary
Annual meeting scheduled for June 10, 2026, at 8:00 AM CDT in Plano, TX.
Shareholders of record as of April 13, 2026, are eligible to vote.
Proxy materials, including the Notice of Meeting, Proxy Statement, and Annual Report, are available online.
Voting matters and shareholder proposals
Election of ten director nominees is on the agenda.
Advisory, non-binding vote to approve executive compensation is included.
Ratification of Ernst & Young LLP as independent auditor for fiscal year ending December 31, 2026.
Approval of Amendment No. 5 to the Second Amended and Restated Stock Purchase Plan is proposed.
Board unanimously recommends voting FOR all director nominees and FOR proposals 2, 3, and 4.
Board of directors and corporate governance
Ten individuals nominated for election to the board.
Board's recommendations are unanimous for all proposals.
Latest events from Orthofix Medical
- Guidance raised on reimbursement restoration and innovation, with focus on organic growth.OFIX
Canaccord Genuity's 46th Annual Growth Conference - Q2 2026 net sales up 4–5% to $210.9M; guidance raised after Medicare reimbursement restored.OFIX
Q2 2026 - Major product launches and commercial realignment position the company for sustainable growth.OFIX
Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Q1 2026 delivered steady growth and margin gains, supporting a strategy for sustained profitability.OFIX
Investor presentation - Q1 2026 saw 3% pro forma sales growth, margin gains, and reaffirmed guidance with improved net loss.OFIX
Q1 2026 - Annual meeting covers director elections, pay, auditor, and stock plan, with strong governance and ESG focus.OFIX
Proxy filing - Margin expansion and innovation pipeline position the business for sustained, profitable growth.OFIX
TD Cowen 46th Annual Health Care Conference - Growth momentum, channel optimization, and innovation set the stage for long-term value creation.OFIX
2026 CG Musculoskeletal Conference - Q4 and 2025 saw strong sales and margin gains, with 2026 guidance targeting further growth.OFIX
Q4 2025